YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Monopar Therapeutics Inc. (MNPR), a clinical-stage biopharmaceutical company, reported financial results for the second quarter of 2026, reflecting a wider net loss, and provided an update on its investigational pipeline. Monop…
(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation. Delcath Systems Inc. (DCTH) Delcath Systems is an interventi…
(RTTNews) - The following biotech stocks reached a 52-week high on July 20, 2026, driven by key catalysts such as upcoming clinical trial launches and the prospective release of data from these studies. Xencor Inc. (XNCR) Xencor is a clini…
(RTTNews) - Biopharmaceutical company Monopar Therapeutics, Inc. (MNPR) announced Tuesday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to ALXN1840 (tiomolibdate choline, TMC), the Co…
WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, tod…
(RTTNews) - Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and…
(RTTNews) - Monopar Therapeutics Inc. (MNPR), on Monday announced that Hepatology Communications has published a peer-reviewed manuscript entitled "Effect of Tiomolibdate Choline on Copper Balance in Patients with Wilson Disease: an Open-l…
WILMETTE, Ill., May 14, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, toda…
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, including Wilson's Disease, Ovaria…
WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, an…
* Monopar Therapeutics press release [https://seekingalpha.com/pr/20454187-monopar-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business] (MNPR [https://seekingalpha.com/symbol/MNPR]): Q4 GAAP EPS of -$0.61 miss…
WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs…
In a welcome move, Broadcom stock saw its Relative Strength Rating improve from 70 to 79 on Monday. See if Broadcom stock can continue to show renewed price strength and clear that threshold. Is Broadcom Stock A Buy? Continue Reading
After a weak first half, the drug and biotech sector regained momentum in the latter part of 2025, setting the stage for a strong year for select stocks. Improved policy clarity following most large drugmakers’ drug pricing agreements with…
* Monopar Therapeutics press release [https://seekingalpha.com/pr/20306013-monopar-therapeutics-reports-third-quarter-2025-financial-results-and-recent-developments] (MNPR [https://seekingalpha.com/symbol/MNPR]): Q3 GAAP EPS of -$0.48 miss…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Northland upgraded DraftKings (DNKG) to Ma…
WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is…
The consensus analyst price target for AstraZeneca has seen a slight upward revision, rising from £138.16 to £140.96, as market expectations are recalibrated. This adjustment comes amid evolving analyst perspectives that balance optimism a…
Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the best hot stocks to invest in. On October 6, Raymond James raised the firm’s price target on Monopar Therapeutics to $142 from $80, while keeping a Strong Buy rating on the shares. The f…
Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology In…
(RTTNews) - "Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we hig…
* Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) announced on Tuesday the pricing of an underwritten registered offering [https://seekingalpha.com/pr/20242206-monopar-therapeutics-inc-announces-pricing-of-135-mil…
(RTTNews) - Monopar Therapeutics Inc. (MNPR) announced the pricing of an underwritten registered offering involving 1.03 million shares of its common stock at $67.67 per share. In addition, certain investors will receive pre-funded warrant…
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics”, “Monopar”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments for patients wit…
WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, to…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded CoreWeave (CRWV) to O…
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, to…
[The New York Stock Exchange on the Wall street sign] Dmitry Vinogradov Oppenheimer has initiated Monopar Therapeutics at outperform citing the potential of a candidate for the genetic disorder Wilson disease it acquired from AstraZeneca (…
* Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) filed $300 million mixed securities shelf. * Filing [https://seekingalpha.com/filing/10365811] MORE ON MONOPAR THERAPEUTICS * Seeking Alpha’s Quant Rating on Monop…
Director Kim R. Tsuchimoto of Monopar Therapeutics (NASDAQ:MNPR), sold 8,904 shares of common stock on July 14, 2025. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, netting approximately $356,170. Th…
Christopher M. Starr, a director at Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025. The company’s stock has shown remarkable performance, with a 1,057% return over the past year, according to Invest…
Chandler Robinson, Chief Executive Officer of Monopar Therapeutics (NASDAQ:MNPR), sold 16,800 shares of common stock on July 14, 2025, according to a recent SEC Filing. The shares were sold at prices ranging from $40.00 to $40.25, for a to…
Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan analyst Keay Nakae began coverage of the company’s stock with a “Buy” rating and a price objective of $60, as…
Investing.com - Chardan Capital Markets initiated coverage on Monopar Therapeutics (NASDAQ:MNPR) with a buy rating and a $60 price target, citing potential in its late-stage Wilson disease treatment and early-stage radiopharmaceutical pipe…
WILMETTE, Ill. and HOUSTON, Texas, June 11, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “us” and “our”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatment…
Monopar Therapeutics (NASDAQ:MNPR [https://seekingalpha.com/symbol/MNPR]) will be added [https://seekingalpha.com/pr/20123970-monopar-therapeutics-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes] to the broad-market Russel…